

ET 2019

EUROPEAN CONFERENCE ON EMBOLOTHERAPY



EMBOLOTHERAPY

POCKET GUIDE

June 26-29

Valencia | Spain

www.ETconference.org

Wednesday, June 26

Thursday, June 27

Friday, June 28

08:00						
15						
30						
45						
09:00	ET 101 UFE MA p13		ET 901 TACE MA p18		ET 1701 PAE MA p22	
15						
30						
45	Break		Break		Break	
10:00						
15						
30	ST 201 Lymphatics Aud. 2 p13	ST 202 Pre-operative venous embol. before liver surgery MA p14	ST 1001 Joints MA p18	ST 1002 Peripheral AVMs Aud. 2 p19	ST 1801 Bariatric Aud. 2 p22	ST 1802 Endoleak MA p23
45						
11:00	Break		Break		Break	
15						
30	CR 301 Thorax/ENT Aud. 2 p14	TF 302 Coils and plugs MA p15	CR 1101 Women's and men's health Aud. 2 p19	TF 1102 Liquids MA p20	CR 1901 AVM/Lymphatics MA p23	TF 1902 Particles Aud. 2 p24
45						
12:00						
15						
30	Lunch break		Lunch break		Lunch break	
45						
13:00	SY 401 Satellite Symposium MA p31		SY 1201 Satellite Symposium MA p35		SY 2001 Satellite Symposium MA p39	
15						
30						
45						
14:00	SY 402 Satellite Symposium MA p33		SY 1202 Satellite Symposium MA p37		SY 2002 Satellite Symposium MA p39	
15						
30	Break		Break		Break	
45						
15:00	CR 501 Abdomen Aud. 2 p16	TF 502 CBCT MA p16	CR 1301 Kidney Aud. 2 p20	TF 1302 Temporary agents MA p21	CR 2101 Portal/Liver MA p25	TF 2102 Microcatheters and microwires Aud. 2 p25
15						
30						
45	Break		Break		Break	
16:00						
15						
30						
45						
17:00	ST 601 Trauma MA p17		ST 1401 Haemorrhoid MA p21		ST 2201 Gonadal veins (female/male) MA p26	
15						
30	Break					
45						
18:00						
	SY 701 Satellite Symposium Aud. 2 p33					

Saturday, June 29

	08:00
	15
	30
ET 2401 TARE	45
	09:00
MA	15
	30
<i>Break</i>	45
	10:00
MM 2501 Morbidity and Mortality Conference – Bad day	15
	30
MA	45
	11:00
<i>Break</i>	15
	30
MM 2601 Morbidity and Mortality Conference – Good day	45
	12:00
MA	15
	30
	45
	13:00

CR: Case Remedy Session

ET: Established Therapy Session

MM: Morbidity and Mortality Conference

ST: Special Topic Session

TF: Technical Focus Session

MA: Main Auditorium

Aud. 2: Auditorium 2




*Session includes lectures
recommended for
EBIR preparation*



e-voting

ET2019

LIVE AND ON DEMAND



library.cirse.org/et2019

Can't decide which session to go to?

Pick one and watch the other lectures on demand in the CIRSE Library!

Interested in more interventional content?

The CIRSE Library is the largest online presentation database for interventional radiology, featuring slides and webcasts from past CIRSE meetings. CIRSE members have year-round free access to all live congresses and webcast recordings. Find out more about our various access options for non-members at cirse.org/library/access.

4 4 Important Addresses 5 5 Scientific Programme Committee 6 6 General Information	
13 Wednesday – Scientific Programme	WED
18 Thursday – Scientific Programme	THU
22 Friday – Scientific Programme	FRI
27 Saturday – Scientific Programme	SAT
29 Corporate Activities 31 Satellite Symposia 41 Learning Centres	
44 Exhibitors and Sponsors 44 Sponsors 46 Exhibitors & Sponsors, Alphabetical list 47 Exhibitors & Sponsors, Numerical list 49 Exhibitors & Sponsors Guide	
Floor plans	

Important Addresses

Congress Venue

Valencia Conference Centre

Avenida de las Cortes Valencianas 60
46015 Valencia, Spain

Organising Secretariat

CIRSE Central Office

Neutorgasse 9
1010 Vienna
Austria

Phone: +43 1 904 2003

Fax: +43 1 904 2003 30

Email: info@cirse.org

www.ETconference.org

The European Conference on Embolotherapy is organised by CIRSE (Cardiovascular and Interventional Radiological Society of Europe).

The official congress website is: www.ETconference.org

To contact the CIRSE Central Office or members of the committee, please write to info@cirse.org

Scientific Programme Committee

Christoph A. Binkert (CH), Chairperson

Patrick Haage (DE), Deputy Chairperson

Enrique Esteban (ES), Local Representative

Thierry de Baère (FR)

Fabrizio Fanelli (IT)

Robert A. Morgan (UK)

Tarun Sabharwal (UK)

Otto M. van Delden (NL)

General Information from A to Z

App

Let the CIRSE app take care of your congress planning! If you do not have the CIRSE society app yet, download it now free of charge for iOS or Android. The ET 2019 event can easily be downloaded within the app and will provide you with a great toolkit to



- build your personal schedule
- submit your session evaluations
- search for exhibitors by product category
- take part in e-voting during sessions
- submit questions to the moderators in select sessions

Badges

Your personalised badge is your admission card to the congress. For organisational and security reasons, badges must be worn at the congress venue at all times. A lanyard will be given to you with the congress bag. Identity checks in the congress centre may occur at any time. In case the badge is lost, a replacement badge will be provided for an administrative charge of €80.

Certificate of Attendance

To obtain your certificate of attendance, you can choose one of the following options:

Print your certificate onsite at the congress

From 10:00 on Friday, June 28, you will be able to use one of the dedicated workstations in the registration area to print your certificate. All you need is your congress badge.

Print your certificate at home

After the congress you will be able to print your certificate of attendance at www.ETconference.org. All you will need is your last name and badge number.

Alternatively, you could log into your CIRSE account at www.ETconference.org with your personal log-in details.

CME Credit Allowance

ET 2019, Valencia, Spain, June 26–29 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 18 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Coffee & Snacks

Refreshments can be purchased at the cash bar opposite the registration area.

Disclaimer

CIRSE cannot accept any liability for the acts of the meeting suppliers or the attendees' safety while travelling to or from the congress. All participants are strongly advised to carry adequate travel and health insurance, as CIRSE cannot accept liability for accidents or injuries that may occur.

Disclosures

For financial disclosures and conflict-of-interest statements, please refer to www.ETconference.org

Evaluation

To submit your session evaluation and obtain credits for your attendance of ET 2019 sessions, please use the online evaluation system, accessible via the CIRSE mobile app (please see page 6) and at programme.et2019.org



Internet

Free wireless service is available to all delegates throughout the congress centre.

Network: ET2019

Password: valencia2019

Live and On Demand – library.cirse.org/et2019

All ET 2019 sessions will be streamed live and will be available on demand in the CIRSE Library shortly after. Never miss another session! CIRSE members have year-round free access to all live congresses and webcast recordings. Find out more about our various access options for non-members at cirse.org/library/access

The CIRSE Library is the largest online presentation database for interventional radiology, featuring slides and webcasts from past CIRSE meetings. With monthly compiled topic packages, the CIRSE Library is the ideal tool for your research and educational needs. Presentations recorded at ET 2019 will be available immediately.

Mobile Phones

Please do not forget to turn your mobile phone to silent mode during the sessions.

Photographs and Video Recording

Please note that any form of recording, filming or photographing of presentation material during the sessions is strictly forbidden. Subject to the authors' consent, all presentation material will be made available online in the CIRSE Library at library.cirse.org

Registration Desk – Opening Hours

Tuesday, June 25	16:00-18:00
Wednesday, June 26	07:30-18:00
Thursday, June 27	08:00-18:00
Friday, June 28	08:00-18:00
Saturday, June 29	08:00-13:00

Smoking

The ET Annual Meeting is a non-smoking congress. Smoking is only permitted outside the congress centre.

Speaker Centre

The Speaker Centre is located on the ground floor. All material must be in English and provided on a CD-ROM, DVD-ROM or USB flash drive (which is preferred) to be placed on the central server onsite. All presentation files must be uploaded at least three hours prior to the beginning of the corresponding session.

Computers connected to the local server allowing access to the speakers' presentations are available in every lecture room. These computers are equipped with Microsoft Windows 10 Professional and Microsoft Office 2016 Professional. Please note that speakers are not allowed to use their own laptops for their presentations.

Speaker Centre – Opening Hours

Tuesday, June 25	16:00-18:00
Wednesday, June 26	07:30-18:00
Thursday, June 27	08:00-18:00
Friday, June 28	08:00-18:00
Saturday, June 29	08:00-12:15

Sponsors & Exhibitors

Please find a floor plan of the exhibition on the inside of the back cover and a detailed list of all exhibitors and sponsors on pages 44-64.

Exhibition – Opening Hours

Wednesday, June 26 09:30-17:30

Thursday, June 27 09:30-17:30

Friday, June 28 09:30-17:30

Saturday, June 29 09:30-12:00

Tourist Information and Hospitality Desk

For information regarding restaurants and excursions, please refer to the desk of our official travel partner Kuoni Congress located in the registration area. Our colleagues from Kuoni Congress will be pleased to help you with all matters related to your stay in Valencia.

CIRSE academy

Your online learning platform for embolisation and beyond

All courses are curated by
leading global experts and tailored
to **EBIR exam preparation**.

You can obtain **CME points**
by completing the **1–2 hour courses**
covering numerous IR topics,
including:

- **Management of acute gastro-intestinal haemorrhage**
- **Vascular trauma**
- **Endovascular management of testicular varicoceles**
- **Prostate artery embolisation**

CME
accredited

Furthering your
IR knowledge –
anytime, anywhere

cirse.org/education/academy



**European Board of
Interventional Radiology**

Apply Now

and boost your career in IR

The EBIR is a globally recognised certification designed to give practising IRs the opportunity to certify their expertise and build their career from early on.

Upcoming examinations:

- **March – ECR 2020**
- **September – CIRSE 2020**

**Submit your application online at
www.cirse.org/ebir**



Cardiovascular and Interventional Radiological Society of Europe

Wednesday, June 26

08:30-09:30, Main Auditorium

Established Therapy Session

ET 101 UFE

*Moderators: C.A. Binkert (Winterthur/CH),
P. Haage (Wuppertal/DE)*



101.1 Patient selection and indication

T.J. Kroencke (Augsburg/DE)



101.2 Procedural aspects

P.N.M. Lohle (Tilburg/NL)



101.3 Patient care and setup

C.A. Binkert (Winterthur/CH)



101.4 Literature and ongoing studies

J.-P. Pelage (Caen/FR)

10:00-11:00, Auditorium 2

Special Topic Session

ST 201 Lymphatics

*Moderators: T. de Baère (Villejuif/FR),
M. Itkin (Philadelphia, PA/US)*

201.1 Retrograde thoracic duct catheterisation: anatomy and technique

M. Inoue (Tokyo/JP)

201.2 Percutaneous lymphography: how I do it

W. Prevoo (Amsterdam/NL)

201.3 Intervention for chylothorax: indication, technique, results

M. Itkin (Philadelphia, PA/US)

201.4 Intervention for chylous ascites

J. Kim (Suwon/KR)



e-voting



recommended for EBIR preparation

10:00-11:00, Main Auditorium

Special Topic Session

ST 202 Pre-operative venous embolisation before liver surgery

*Moderators: E. Brountzos (Athens/GR),
A. Denys (Lausanne/CH)*



202.1 Indications for PVE in cirrhotic and non-cirrhotic liver

E. Brountzos (Athens/GR)



202.2 Which is the best embolic for PVE

Y. Arai (Tokyo/JP)

202.3 Technical aspects of liver deprivation

C.A. Binkert (Winterthur/CH)

202.4 ALPPS versus liver deprivation: differences in results

B. Guiu (Montpellier/FR)

11:15-12:15, Auditorium 2



Case Remedy Session

CR 301 Thorax/ENT

*Moderators: A. Krajina (Hradec Králové/CZ),
M.J. Lee (Dublin/IE)*

301.1 Bronchial artery embolisation – benign

A.H. Mahnken (Marburg/DE)

301.2 Bronchial artery embolisation – malignant

J.-Y. Gaubert (Marseille/FR)

301.3 PAVMs

A. Alsafi (London/UK)

301.4 Epistaxis

A. Krajina (Hradec Králové/CZ)

11:15-12:15, Main Auditorium

Technical Focus Session

TF 302 Coils and plugs

*Moderators: S. Müller-Hülsbeck (Flensburg/DE),
J.-P. Pelage (Caen/FR)*

- 302.1 Description of use and concept
D. Vorwerk (Ingolstadt/DE)
- 302.2 Framing and packing
G. Maleux (Leuven/BE)
- 302.3 Plugs
L. Hechelhammer (St. Gallen/CH)
- 302.4 Complications and their management
J.-P. Pelage (Caen/FR)

12:45-13:30, Main Auditorium

SY 401 Satellite Symposium

For the programme, please refer to page 31.

13:30-14:15, Main Auditorium

SY 402 Satellite Symposium

For the programme, please refer to page 33.



e-voting



recommended for EBIR preparation



14:30-15:30, Auditorium 2

Case Remedy Session

CR 501 Abdomen

*Moderators: A.H. Mahnken (Marburg/DE),
O.M. van Delden (Amsterdam/NL)*

- 501.1 Upper GI bleeding
J. Urbano (Madrid/ES)
- 501.2 Lower GI bleeding
O.M. van Delden (Amsterdam/NL)
- 501.3 Splenic size reduction
E. Esteban (Valencia/ES)
- 501.4 Visceral aneurysm
P. Lucatelli (Rome/IT)

14:30-15:30, Main Auditorium

Technical Focus Session

TF 502 CBCT

*Moderators: F. Orsi (Milan/IT),
L. Tselikas (Villejuif/FR)*

- 502.1 Description of use and concept
T. Tanaka (Kashihara/JP)
- 502.2 Vascular navigation planning
L. Tselikas (Villejuif/FR)
- 502.3 Perfusion area
M. Das (Duisburg/DE)
- 502.4 Angio-CT vs cone-beam CT
B. Guiu (Montpellier/FR)

16:00-17:00, Main Auditorium

Special Topic Session

ST 601 Trauma

*Moderators: S. Müller-Hülsbeck (Flensburg/DE),
R. Uberoi (Oxford/UK)*



601.1 Work-up and logistics
O.M. van Delden (Amsterdam/NL)



601.2 Liver and splenic injury
S. Pal (Dundee/UK)



601.3 Pelvic fracture
S. Müller-Hülsbeck (Flensburg/DE)



601.4 Thoracic trauma
A. Moelker (Rotterdam/NL)

17:15-17:35, Auditorium 2

SY 701 Satellite Symposium

For the programme, please refer to page 33.



e-voting



recommended for EBIR preparation

Thursday, June 27

08:30-09:30, Main Auditorium

Established Therapy Session

ET 901 TACE

*Moderators: K. Malagari (Athens/GR),
P.L. Pereira (Heilbronn/DE)*



901.1 Patient selection and indication

P.L. Pereira (Heilbronn/DE)



901.2 Procedural aspects

S. Sugawara (Tokyo/JP)



901.3 Patient care and setup

F. Orsi (Milan/IT)



901.4 Literature and ongoing studies

T. de Baère (Villejuif/FR)

10:00-11:00, Main Auditorium

Special Topic Session

ST 1001 Joints

*Moderators: M.E. Krokidis (Cambridge/UK),
Y. Okuno (Tokyo/JP)*

1001.1 Catheters and embolics

Y. Okuno (Tokyo/JP)

1001.2 Frozen shoulder

A.M. Fernández Martínez (Leon/ES)

1001.3 Knee-haemarthrosis

M.W. Little (Reading/UK)

1001.4 Osteoarthritis: who to treat, how to follow-up
and what are the complications

R.D. García-Mónaco (Buenos Aires/AR)

10:00-11:00, Auditorium 2

Special Topic Session

ST 1002 Peripheral AVMs

*Moderators: T. Sabharwal (London/UK),
W.A. Wohlgemuth (Halle/DE)*

- 1002.1 Diagnosis and classification
M. Köcher (Olomouc/CZ)
- 1002.2 Low flow malformation: technique and outcome
J.A. Reekers (Amsterdam/NL)
- 1002.3 High flow malformation
I. McCafferty (Birmingham/UK)
- 1002.4 Complex and microcystic lymphatic malformation
W.A. Wohlgemuth (Halle/DE)

11:15-12:15, Auditorium 2



Case Remedy Session

CR 1101 Women's and men's health

*Moderators: T.J. Kroencke (Augsburg/DE),
P.N.M. Lohle (Tilburg/NL)*

- 1101.1 Post-partum haemorrhage
(abnormal placentation)
L. Ratnam (London/UK)
- 1101.2 Adenomyosis
P.N.M. Lohle (Tilburg/NL)
- 1101.3 Priapism
L.B. Lönn (Copenhagen/DK)
- 1101.4 PAE: coil protection embolisation (radial access)
T. Bilhim (Lisbon/PT)



e-voting



recommended for EBIR preparation

11:15-12:15, Main Auditorium

Technical Focus Session

TF 1102 Liquids

*Moderators: I. McCafferty (Birmingham/UK),
F. Wolf (Vienna/AT)*

1102.1 Description of use and concept

I. McCafferty (Birmingham/UK)

1102.2 Glue/EVOH

J. Urbano (Madrid/ES)

1102.3 Sclerosing/Foam

J.A. Reekers (Amsterdam/NL)

1102.4 Complications

K.A. Hausegger (Klagenfurt/AT)

12:45-13:30, Main Auditorium

SY 1201 Satellite Symposium

For the programme, please refer to page 35.

13:30-14:15, Main Auditorium

SY 1202 Satellite Symposium

For the programme, please refer to page 37.

14:30-15:30, Auditorium 2



Case Remedy Session

CR 1301 Kidney

*Moderators: B.A. Radeleff (Hof/DE),
L. Tselikas (Villejuif/FR)*

1301.1 AML embolisation

M.J. Lee (Dublin/IE)

1301.2 Angionephrectomy

L. Tselikas (Villejuif/FR)

1301.3 Pre-operative RCC metastasis embolisation

N. Thulasidasan (London/UK)

1301.4 Kidney trauma

C.J. Zech (Basel/CH)

14:30-15:30, Main Auditorium

Technical Focus Session

TF 1302 Temporary agents

*Moderators: T.J. Kroencke (Augsburg/DE),
R.A. Morgan (London/UK)*

1302.1 Description of use and concept

T.J. Kroencke (Augsburg/DE)

1302.2 Gelfoam

A. Krajina (Hradec Králové/CZ)

1302.3 Absorbable microspheres

N. Hacking (Southampton/UK)

1302.4 Complications and their management

F. Wolf (Vienna/AT)

16:00-17:00, Main Auditorium

Special Topic Session

ST 1401 Haemorrhoid

*Moderators: M.D. Ferrer-Puchol (Alzira/ES),
V. Vidal (Marseille/FR)*

1401.1 Patient selection, classification and
surgical options

M.R. Sapoval (Paris/FR)

1401.2 Anatomy and catheterisation

A. Rebonato (Perugia/IT)

1401.3 Technical aspects: which embolics?

E. Esteban (Valencia/ES)

1401.4 Outcome and results

V. Vidal (Marseille/FR)



e-voting



recommended for EBIR preparation

Friday, June 28

08:30-09:30, Main Auditorium

Established Therapy Session

ET 1701 PAE

*Moderators: T. Bilhim (Lisbon/PT),
T. Sabharwal (London/UK)*



1701.1 Patient selection and indication
L. Hechelhammer (St. Gallen/CH)



1701.2 Procedural aspects
M.R. Sapoval (Paris/FR)



1701.3 Patient care and setup
T. Bilhim (Lisbon/PT)



1701.4 Literature and ongoing studies
N. Hacking (Southampton/UK)

10:00-11:00, Auditorium 2

Special Topic Session

ST 1801 Bariatric

*Moderators: C.A. Binkert (Winterthur/CH),
V. Vidal (Marseille/FR)*

1801.1 Bariatric surgery standards and the possible role
of embolisation
M.-D. Frey (Wetzikon/CH)

1801.2 Animal data
M.D. Kim (Seoul/KR)

1801.3 Human data
C.R. Weiss (Baltimore, MD/US)





1801.4 Y-90 to enhance the effect
C.R. Weiss (Baltimore, MD/US)

10:00-11:00, Main Auditorium

Special Topic Session

ST 1802 Endoleak

*Moderators: F. Fanelli (Florence/IT),
P. Reimer (Karlsruhe/DE)*

-  1802.1 Which endoleaks require embolisation?
F. Fanelli (Florence/IT)
-  1802.2 Type I endoleaks
M.W. de Haan (Maastricht/NL)
-  1802.3 Type II endoleaks
R.A. Morgan (London/UK)
-  1802.4 Type V endoleaks
R. Uberoi (Oxford/UK)

11:15-12:15, Main Auditorium



Case Remedy Session

CR 1901 AVM/Lymphatics

*Moderators: P. Rowlands (Liverpool/UK),
J.A. Reekers (Amsterdam/NL)*

- 1901.1 Direct puncture AVM treatment
A. Bisdorff (Paris/FR)
- 1901.2 Large AV shunt
P. Rowlands (Liverpool/UK)
- 1901.3 Transvenous nidus embolisation
W.A. Wohlgemuth (Halle/DE)
- 1901.4 Thoracic duct embolisation (leakage)
M. Itkin (Philadelphia, PA/US)



e-voting



recommended for EBIR preparation

11:15-12:15, Auditorium 2

Technical Focus Session

TF 1902 Particles

*Moderators: J.-F.H. Geschwind (Westport, CT/US),
J.-P. Pelage (Caen/FR)*

- 1902.1 Description of use and concept
J.-F.H. Geschwind (Westport, CT/US)
- 1902.2 Radiopaque microspheres
P.L. Pereira (Heilbronn/DE)
- 1902.3 New drugs for microspheres
A. Denys (Lausanne/CH)
- 1902.4 Complications and their management
E. Brountzos (Athens/GR)



12:45-13:30, Main Auditorium

SY 2001 Satellite Symposium

For the programme, please refer to page 39.

13:30-14:15, Main Auditorium

SY 2002 Satellite Symposium

For the programme, please refer to page 39.



14:30-15:30, Main Auditorium

Case Remedy Session

CR 2101 Portal/Liver

*Moderators: C.A. Binkert (Winterthur/CH),
P. Chevallier (Nice/FR)*

- 2101.1 BRTO/PRTO
W.E.A. Saad (Charlottesville, VA/US)
- 2101.2 Venous double embolisation (liver deprivation)
P. Chevallier (Nice/FR)
- 2101.3 Balloon TACE
B.A. Radeleff (Hof/DE)
- 2101.4 Extrahepatic feeder
S. Sugawara (Tokyo/JP)

14:30-15:30, Auditorium 2

Technical Focus Session

TF 2102 Microcatheters and microwires

*Moderators: T. de Baère (Villejuif/FR),
G. Maleux (Leuven/BE)*

- 2102.1 Different features and designs
M.E. Krokidis (Cambridge/UK)
- 2102.2 Balloon and antireflux
T. de Baère (Villejuif/FR)
- 2102.3 Steerable microcatheters
Y. Arai (Tokyo/JP)
- 2102.4 Tips and tricks in neurointervention
F. Brassel (Duisburg/DE)



e-voting



recommended for EBIR preparation

16:00-17:00, Main Auditorium

Special Topic Session

ST 2201 Gonadal veins (female/male)

*Moderators: P. Haage (Wuppertal/DE),
N. Thulasidasan (London/UK)*

- 2201.1 Pelvic congestion syndrome: what is it?
M.A. de Gregorio (Zaragoza/ES)
- 2201.2 Techniques for PCS: anatomy and embolics
N. Thulasidasan (London/UK)
- 2201.3 Varicocele: who should be treated?
P. Reimer (Karlsruhe/DE)
- 2201.4 Bilateral varicocele: what is different about
the right side
A.H. Mahnken (Marburg/DE)

Saturday, June 29

08:30-09:30, Main Auditorium

Established Therapy Session

ET 2401 TARE

*Moderators: T.K. Helmberger (Munich/DE),
K. Malagari (Athens/GR)*



2401.1 Patient selection and indication

T.K. Helmberger (Munich/DE)



2401.2 Radiation segmentectomy

R.J. Lewandowski (Chicago, IL/US)



2401.3 Optimising dosimetry: Ho-166 and Y-90

M.G.E.H. Lam (Utrecht/NL)



2401.4 Literature and ongoing studies

R.J. Lewandowski (Chicago, IL/US)

10:00-11:00, Main Auditorium



Morbidity and Mortality Conference

MM 2501 Bad day

*Moderators: E. Brountzos (Athens/GR),
F. Fanelli (Florence/IT)*

2501.1 Filter surprise

M. Hadi (Oxford/UK)

2501.2 Uterine artery embolisation nightmare

T. Sabharwal (London/UK)

2501.3 Choosing between two evils

O.M. van Delden (Amsterdam/NL)

2501.4 A perplexing case of GI bleeding

M.J. Lee (Dublin/IE)



e-voting



recommended for EBIR preparation



11:15-12:15, Main Auditorium

Morbidity and Mortality Conference

MM 2601 Good day

*Moderators: C.A. Binkert (Winterthur/CH),
P. Haage (Wuppertal/DE)*

- 2601.1 TACE: can't believe it's true!
I. Bargellini (Pisa/IT)
- 2601.2 Curse of good deed – three times is enough
D. Vorwerk (Ingolstadt/DE)
- 2601.3 How I met my Waterloo
B.A. Radeleff (Hof/DE)
- 2601.4 Superselective treatment – diffuse damage:
a complicated DEB-TACE
T.K. Helmberger (Munich/DE)

ET 2019

EUROPEAN CONFERENCE ON EMBOLOTHERAPY



CORPORATE ACTIVITIES & EXHIBITION


Satellite Symposia
Learning Centres
Exhibitors & Sponsors



Cardiovascular and Interventional Radiological Society of Europe

Boost occlusive capacity with fiber.

Polymer fibers allow significantly fewer embolization coils to achieve acute occlusion of arteries than bare metal coils.¹



Visit cookmedical.eu/FiberStudy
Learn about the impact of fiber from
peer-reviewed, statistically significant
in-vivo data.



1. Nylon Fibered versus Non-fibered Embolization Coils:
Comparison in a Swine Model. Scott O. Trerotola, MD;
Gary A. Pressler, and Christopher Premanandan, (In Press,
Journal of Vascular and Interventional Radiology)

Satellite Symposia

Wednesday, June 26

12:45-13:30, Main Auditorium

Cook Medical

SY 401 Fibered coils from research to patient

- 401.1 Fibered versus non-fibered embolisation coils:
how fiber on coils affects their function and value
P. Diwakar (Liverpool/UK)
- 401.2 From package to patient with precision: the
evolution of pelvic venous coil embolisation
D. Beckett (Bournemouth/UK)

YOUR PARTNER FOR EMBOLIZATION SOLUTIONS

MVP™

Micro Vascular Plug System



RELIABLE DEPLOYMENT
RAPID OCCLUSION

Onyx™

Liquid Embolic System



THE ADVANTAGE OF TIME
THE POWER OF CONTROL

Concerto™

3D Detachable Coil System



Concerto™

Helix Detachable Coil System



CONTROLLED PRECISION
RELIABLY DELIVERED

medtronic.com/apv

UC201804329aEE © Medtronic 2019.
All rights reserved. Printed in Europe.

Medtronic
Further. Together

Wednesday, June 26

13:30-14:15, Main Auditorium

Medtronic

SY 402 Emerging indications and solutions in embolotherapy

Moderator: C.A. Binkert (Winterthur/CH)

- 402.1 Welcome & Introduction
C.A. Binkert (Winterthur/CH)
- 402.2 Super-selective embolisation of distal GI bleedings with Onyx™
J. Urbano (Madrid/ES)
- 402.3 Onyx™ embolisation for the occlusion of the proximal internal iliac artery during EVAR
H. Lindgren (Helsingborg/SE)
- 402.4 Expanding embolisation options with the MVP™ Micro Vascular Plug System
G. Maleux (Leuven/BE)
- 402.5 Final remarks and closing
C.A. Binkert (Winterthur/CH)

17:15-17:35, Auditorium 2

Balt International

SY 701 α-hexyl-cyanoacrylate vs EVOH agent: different indications for different liquid embolic agents

- 701.1 α-hexyl-cyanoacrylate vs EVOH agent: different indications for different liquid embolic agents
W.A. Wohlgemuth (Halle/DE)

VECTORIO®

cTACE Mixing & Injection System

Vectorio® efficacy & safety for improved cTACE mixing & delivery



UNBREAKABLE | USER-FRIENDLY | SHARP

Guerbet | ■■■

LIPIODOL® ULTRA-FLUID. Composition: Ethyl esters of iodized fatty acids of poppy seed oil 10 mL, corresponding to an iodine content of 480 mg/mL. **Indications (**):** In diagnostic radiology - Hysterosalpingography - Ascending urethrography - Lymphography - Sialography - Fistulography and exploration of abscesses - Exploration of frontal sinuses - Pre and post-operative cholangiography. In interventional radiology - Visualisation and localization (by selective intra-arterial use during CT) of liver lesions in adults with known or suspected hepatocellular carcinoma - Visualisation, localisation and vortisation during Trans-Arterial Chemo-Embolisation (TACE) of hepatocellular carcinoma at intermediate stage, in adults - Selective embolization in combination with Histoacryl glue (particularly for arteriovenous malformation or aneurysms) - Selective injections of LIPIODOL ULTRA-FLUID into the hepatic artery for diagnostic purposes where a spiral CT scan is not practical. In endocrinology - Prevention of severe cases of iodine deficiency. **Posology and method of administration (*):** have to be adapted according to the type of examination, the territories explored, the age and weight of the patient. The volume to be administered depends on the particular requirements of the technique and the size of the patient. **Contraindications:** Hypersensitivity to LIPIODOL ULTRA-FLUID - Confirmed hyperthyroidism - Patients with traumatic injuries, recent haemorrhage or bleeding - Hysterosalpingography during pregnancy or acute pelvic inflammation - Bronchography. In interventional radiology (Trans-Arterial Chemo-Embolisation), Administration in liver areas with dilated bile ducts unless drainage has been performed. **Special warnings and special precautions for use (*):** There is a risk of hypersensitivity regardless of the dose administered. Lymphography: Pulmonary embolism may occur immediately or after few hours to days from inadvertent systemic vascular injection or intravasation of LIPIODOL ULTRA-FLUID: Perform radiological monitoring during LIPIODOL ULTRA-FLUID injection and avoid use in patients with severely impaired lung function, cardiorespiratory failure or right-sided cardiac overload. **Hypersensitivity:** all iodinated contrast agents can lead to minor or major hypersensitivity reactions, which can be life-threatening. These hypersensitivity reactions are of an allergic nature (known as anaphylactic reactions if they are serious) or a non-allergic nature. They can be immediate (occurring within 60 min) or delayed (not occurring until up to 7 days later). Anaphylactic reactions are immediate and can be fatal. They are dose-independent, can occur right from the first administration of the product, and are often unpredictable: avoid use in patients with a history of sensitivity to other iodinated contrast agents, bronchial asthma or allergic disorders because of an increased risk of a hypersensitivity reaction to LIPIODOL ULTRA-FLUID. **Thyroid:** can cause hyperthyroidism in predisposed patients. Lymphography saturates the thyroid with iodine for several months and thyroid exploration should be performed before radiological examination. **Chemo-Embolisation:** Trans-Arterial Chemo-Embolisation is not recommended in patients with decompensated liver cirrhosis (Child-Pugh ≥8), advanced liver dysfunction, macroscopic invasion and/or extra-hepatic spread of the tumour. Renal insufficiency must be prevented by correct rehydration before and after the procedure. Oesophageal varices must be carefully monitored. Hepatic intra-arterial treatment can progressively cause an irreversible liver insufficiency in patients with serious liver malfunction and/or undergoing close multiple sessions. The risk of superinfection in the treated area is normally prevented by administration of antibiotics. **Embolization with glue:** An early polymerisation reaction may exceptionally occur between LIPIODOL ULTRA-FLUID and certain surgical glues, or even certain batches of glue. Before using new batches of LIPIODOL ULTRA-FLUID or surgical glue, the compatibility of LIPIODOL ULTRA-FLUID and the glue must be tested in vitro. **Interaction with other medicinal products and other forms of interaction (*):** Metformin, Beta blockers, vasoactive substances, angiotensin-converting enzyme inhibitors, angiotensin-receptor antagonists, Diuretics, Interleukin II. **Fertility, pregnancy and lactation (*):** LIPIODOL ULTRA-FLUID must only be used in pregnant women if absolutely necessary and under strict medical supervision. Breastfeeding should be discontinued if LIPIODOL ULTRA-FLUID must be used. **Effects on ability to drive and use machines:** The effects on ability to drive and to use machines have not been investigated. **Undesirable effects (*):** Most adverse effects are dose-related and dosage should therefore be kept as low as possible: hypersensitivity, anaphylactic reaction, anaphylactoid reaction, vomiting, diarrhoea, nausea, fever, pain, dyspnoea, cough, hypothyroidism, hyperthyroidism, thyroiditis, pulmonary embolism, cerebral embolism, retinal vein thrombosis, lymphoedema aggravation, hepatic vein thrombosis, granuloma. **Overdose (*):** The total dose of LIPIODOL ULTRA-FLUID administered must not exceed 20 mL. **Pharmacodynamic properties (*):** Pharmacotherapeutic group: X-ray contrast media, iodinated; ATC code: V08A D01. Water-insoluble iodinated contrast medium. **Presentation (*):** 10 mL glass ampoule. **Marketing authorization holder (*):** Guerbet - BP 57400 - F-95943 Roissy CdG cedex - FRANCE. Information: tel: 33 (0) 1 45 91 50 00. **Revision:** April 24th, 2018.

(*) For complete information please refer to the local Summary of Product Characteristics (SPC).

(**) Indications, volumes and presentations may differ from country to country.

Reporting of suspected adverse reactions is important as it helps to continuously assess the benefit-risk balance. Therefore, Guerbet encourages you to report any adverse reactions to your health authorities or to our local Guerbet representative.

VECTORIO® is a medical device of Class Is (CE 0459) intended to be used by healthcare professionals only. Manufacturer: Medex, a Guerbet Group company. **Intended use:** Lipiodol® Resistant Mixing & Injection System for conventional Trans-Arterial Chemo-Embolization (cTACE).

For complete information please refer to country's local Package Information Leaflet & Vectorio® Instruction For Use (IFU).

Countries in which cTACE indication is registered: Austria, Argentina, Belgium, Brazil, Cambodia, Czech Republic, France, Japan, Hong Kong, Hungary, Ireland, India, Iran, Luxembourg, Mexico, Mongolia, New Zealand, Peru, Portugal, Philippines, South Korea, Turkey, The Netherlands, Thailand, Taiwan, Tunisia, Vietnam.

For a copy of the SPC/ IFU, please contact a member of Guerbet.

Thursday, June 27

12:45-13:30, Main Auditorium

Guerbet

SY 1201 Non-target embolisation: an ignored problem!

Moderator: I. Bargellini (Pisa/IT)

1201.1 Non-target embolisation: from concept to clinical situation

T. de Baère (Villejuif/FR)

1201.2 Prostate artery embolisation, how to secure our practice

T. Bryant (Southampton/UK)

TAKE CONTROL OF SMALL VESSEL EMBOLIZATION

- AZUR® CX coil provides superior cross-sectional coverage with unique coil design and is now available in 2 and 3 mm sizes, for expanded treatment options
- Progreat® microcatheter allows you to easily access small vasculature e.g. in the GI tract



from ACCESS
to CLOSURE
INTERVENTIONAL
ONCOLOGY



PUSHING BOUNDARIES

TERUMO
INTERVENTIONAL
SYSTEMS

Not all products are available for sale in all countries. This information is provided only in respect to markets where these products are approved or cleared. All products are not cleared or approved in the U.S.A. by the Food and Drug Administration. Please contact your Terumo local sales representative for more information.

IS765GB0419IT11

Thursday, June 27

13:30-14:15, Main Auditorium

Terumo Interventional Systems

SY 1202 The Pearls of TACE

*Moderators: T. de Baère (Villejuif/FR),
P.L. Pereira (Heilbronn/DE)*

- 1202.1 Introduction
T. de Baère (Villejuif/FR)
- 1202.2 Pearls of mCRC: evidence, opportunities,
optimisations...
P.L. Pereira (Heilbronn/DE)
- 1202.3 Discussion and audience interaction
- 1202.4 Pearls of HCC: patient, drugs, tolerance, efficacy,
future trends...
T. de Baère (Villejuif/FR)
- 1202.5 Discussion and audience interaction
- 1202.6 Take home message
P.L. Pereira (Heilbronn/DE)



DIREXION™

Torqueable Microcatheter

Wherever you
want to go.



DIREXION™ is a registered or unregistered trademark of Boston Scientific Corporation.

All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for the use only in countries with applicable health authority product registrations. Material not intended for use in France.

PI-582303-AA © 2019 Boston Scientific Corporation or its affiliates. All rights reserved.

Friday, June 28

12:45-13:30, Main Auditorium



Boston Scientific

SY 2001 Which embolics and why? Case studies with the experts

Moderator: C.A. Binkert (Winterthur/CH)

- 2001.1 Case discussions: trauma & elective
V. Vidal (Marseille/FR)
- 2001.2 Case discussions: trauma & elective
G. Maleux (Leuven/BE)
- 2001.3 Case discussions: trauma & elective
F. Wolf (Vienna/AT)

13:30-14:15, Main Auditorium

Abbott Vascular

SY 2002 Pelvic congestive syndrome – adequate diagnosis and treatment alternatives

Moderator: C.A. Binkert (Winterthur/CH)

- 2002.1 Prevalence and diagnosis of PCS
N. Lopez (Barcelona/ES)
- 2002.2 Imaging and treatment strategy for PCS
C.A. Binkert (Winterthur/CH)
- 2002.3 Treatment with vascular plugs – my experience
M.A. de Gregorio (Zaragoza/ES)



ET MEETS **GEST** 2020

EUROPEAN CONFERENCE ON EMBOLOTHERAPY

EMBOLOTHERAPY

June 24-27
Vienna | Austria

www.ETconference.org

CIRSE Cardiovascular and Interventional Radiological Society of Europe

Learning Centres

The Learning Centres at ET 2019 will provide an excellent opportunity for all congress delegates to test the latest interventional devices, gain hands-on experience with new equipment and talk to industry representatives.

Please note that CIRSE is not responsible for the information provided at the Learning Centres.

Cook Medical

Visit our balcony to participate in our **“EndoWars”**.

A hands-on challenge to test your skills at deploying and tightly packing a certain number of embolisation coils in the shortest amount of time. Try your hand at beating the best!

The physician with the fastest time earns an opportunity to attend a Cook Medical European Vista® Education and Training course of their choice. There are several opportunities each day during ET for you to participate in this game.

Guerbet

Guerbet, Interventional Imaging, is offering interactive programmes on devices designed to secure your embolisation procedures.

Join Guerbet experts within our Innovation Labs for interactive hands-on sessions from June 26 to 29.

Learn more on cTACE mixture standardisation using Vectorio®

Wednesday, Thursday, Friday

09:30-10:00

11:00-11:15

14:15-14:30

15:30-16:00

17:00-17:15

Saturday

09:30-10:00

11:00-11:15

Innovation Lab Vectorio®

Discover Sequester® Control Reflux microcatheter – flow dynamics based technology

Wednesday, Thursday, Friday

09:30-10:00

11:00-11:15

14:15-14:30

15:30-16:00

17:00-17:15

Saturday

09:30-10:00

11:00-11:15

Innovation Lab Sequester®

Medtronic

The Medtronic Learning Centre is for physicians experienced in embolisation and interested to learn more about Medtronic embolisation portfolio.

Objectives

Participants will be able to:

1. Learn the key features & benefits of each embolic agent in Medtronic's embolisation portfolio
2. Understand the mode of operation of Onyx liquid embolisation
3. Learn about Medtronic's medical education programs and how to enrol

Wednesday, June 26

11:15-12:15

14:30-15:30

Thursday, June 27

11:15-12:15

14:30-15:30

Friday, June 28


11:15-12:15

14:30-15:30

Programme

- Welcome and objective
- Medtronic's embolisation portfolio
- Medtronic's medical education programs for embolisation
- Introduction to vascular flow model
- Onyx™ Liquid Embolic System hands-on demonstration in flow model
- Extra hands-on time for participants who wish to stay longer

Diamond Sponsors



DIAMOND



Guerbet | 

C|RSE

Gold | Silver | Other Sponsors



Gold Sponsors

Abbott
Balt
Boston Scientific
Medtronic
Merit Medical
Terumo

Silver Sponsors

BTG
Penumbra
Sirtex

Other Sponsors

GEM
Interventional News / BIBA

Exhibitors & Sponsors (Alphabetical List)

Company	Booth #
Abbott Vascular	*
Balt International	7
Boston Scientific International	*
BTG	12
CIREL	15
CIRSE Academy	8
CIRSE Library	9
CIRT-FR	14
Cook Medical	6
CVIR	17
CVIR Endovascular	16
EBIR	11
Endovascular Today Europe	10a
GEM	13
Guerbet	4
Interventional News / BIBA	10
Medtronic International	*
Merit Medical	5
Penumbra Europe	2
Sirtex Medical Europe	3
Terumo Europe	1

* Corporate sponsors not exhibiting

Exhibitors & Sponsors (Numerical List)

Company	Booth #
Terumo Europe	1
Penumbra Europe	2
Sirtex Medical Europe	3
Guerbet	4
Merit Medical	5
Cook Medical	6
Balt International	7
CIRSE Academy	8
CIRSE Library	9
Interventional News / BIBA	10
Endovascular Today Europe	10a
EBIR	11
BTG	12
GEM	13
CIRT-FR	14
CIREL	15
CVIR Endovascular	16
CVIR	17
Abbott Vascular	*
Boston Scientific International	*
Medtronic International	*

* Corporate sponsors not exhibiting

squidperi & magic glue

Satellite Symposium:
**α-hexyl-cyanoacrylate
Vs EVOH agent:
different indications
for different liquid
embolic agents**

by Prof W. Wohlgemuth
Wednesday, June 26, 2019
5:15pm, Auditorium II



Magic Glue is a liquid embolic agent indicated in the embolization of arteriovenous malformation. Manufactured by Peters Surgical SAS, 42 rue Benoit Frachon, 93013 Bobigny Cedex, France. Class III CE 0459 in compliance with Medical Device Directive (MDD 93/42/EEC amended by 2007/47/EC). First CE marking: 2018. Carefully read the instructions for use before use. Product distributed by Balt Extrusion SAS.

SQUIDPERI is intended to the embolisation of lesions in the peripheral vasculature, including arteriovenous malformations and hypervascular tumors. Class IIb CE0297 in compliance with Medical Device Directive (MDD 93/42/EEC amended by 2007/47/EC). Manufactured by EMBO-FLÜSSIGKEITEN A.G. Carefully read the instructions for use before use. Not reimbursed. First CE marking: 2013. The content of this document, in particular data, information, trademarks and logos is BALT SAS and affiliates' sole property. © 2019 BALT SAS and affiliates, all rights reserved. All representation and/or reproduction, whether in part or in full, is forbidden and would be considered a violation of BALT SAS and affiliates' copyrights and other intellectual proprietary rights. This document with associated pictures is non-contractual and is solely dedicated to healthcare professionals and BALT's distributors (BALT's supplier's distributors). It cannot be distributed or given to patients. The products commercialized by BALT shall exclusively be used in accordance with the instructions for use included in the boxes. ADI2019/003 (04/2019)

Exhibitors & Sponsors Guide

Abbott Vascular

Park Lane
Culliganlaan 2B
1831 Diegem
BELGIUM
www.vascular.abbott



*

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 103,000 colleagues serve people in more than 160 countries. Connect with us at www.AbbottatEuroPCR.com, www.cardiovascular.abbott and on Twitter @Abbottcardio, @AbbottNews, and @AbbottGlobal.

Balt International

10 rue Croix Vigneron
95160 Montmorency
FRANCE
www.balt.fr




7

BALT aims to be the trusted partner physicians want to work with, by delivering only the best & breakthrough solutions in the endovascular treatment of vascular diseases worldwide.

** Corporate sponsors not exhibiting*

UTILITY BEYOND VISIBILITY

Visit us on the booth to get hands-on with
DC Bead LUMI™ and explore the benefits
of radiopaque embolic microspheres.



DC Bead™

DC Bead LUMI™

Bead Block™



Bead Block, DC Bead and DC Bead LUMI are manufactured by and are trademarks of Biocompatibles UK Ltd, a BTG International group company. BTG and the BTG roundel logo are trademarks of BTG International Ltd. BTG and the BTG roundel logo are registered trademarks in the US, EU and certain other territories. All rights reserved. © 2019 Biocompatibles UK Ltd. CE-BB-1900016 EMEA. Date of preparation April 2019. Marcomms

Boston Scientific International SA

Parc d'Affaires Val Saint Quentin –

Bâtiment H

2 Rue René Caudron

78960 Voisins-le-Bretonneux

FRANCE

Phone: +33 1 39 30 9700

E-Mail: ReceptionFrance@bsci.com

www.bostonscientific.eu



*

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.

BTG

Lakeview, Riverside Way

Watchmoor Park, Camberley

GU15 3YL Surrey

UNITED KINGDOM

btg-io.com

**12**

BTG Interventional Oncology is transforming the way cancer is treated with our wide-ranging solutions of minimally-invasive, highly targeted cancer therapies. We are leaders in developing intelligent, loco-regional treatments that can be personalised to each patient's needs. Our treatments include elegant and innovative new medicines, improved device technology and ground-breaking delivery techniques.

Our products are used to treat and provide symptomatic relief for people with cancer and benign tumours.

By specifically targeting diseased cells, we can limit the impact on healthy tissue. Our solutions include embolisation beads, drug-eluting beads, radiotherapy treatment that uses yttrium-90 glass microspheres, and cryoablation delivery systems.

** Corporate sponsors not exhibiting*

By partnering with the brightest minds in medicine and technology, we are committed to better serving healthcare professionals and delivering improved healthcare for those who deserve it the most, the patients. Healthcare is evolving and at BTG Interventional Oncology we believe intelligent science is the way forward.

To learn more about BTG Interventional Oncology, please visit: btg-io.com.

CIREL

15

CIREL is a European-wide, prospective, observational (non-interventional) study that gathers data on transarterial chemoembolisation (TACE) using LifePearl Microspheres loaded with irinotecan (LP-IRI) in patients with colorectal cancer (CRC) with liver metastatic disease. The registry observes the real-life use of the device in the context of the patients' entire cancer treatment and collects extensive data regarding safety and toxicity, efficacy and treatment-related quality of life. The collection of real-life data is intended to form an evidence-base from which conclusions can be drawn on how to improve patient selection and optimise treatment protocols to ultimately improve the therapy outcome of patients treated with TACE performed with LifePearl Microspheres.

CIRSE Academy**8**

The CIRSE Academy is an online learning platform offering a range of e-learning courses uniquely tailored to the European Curriculum for IR. The CIRSE Academy currently comprises a total of 23 courses covering seven IR topics. All courses are authored and reviewed by leading IR experts and include a blend of texts, graphics, videos and a multiple-choice quiz to further your learning. Finishing a CIRSE Academy course will earn you 1-2 CME points within just 1-2 hours. Find out more at the CIRSE Academy booth or online at <https://www.cirse.org/education/academy/>

CIRSE Library**9**

The CIRSE Library is IR's most comprehensive resource for congress content. Find all lectures and posters from the CIRSE, ECIO, GEST Europe/ET and IROS congresses since 2014, watch webcasts in HD quality, browse our large collection of educational topic packages, get recommendations for similar content, and find selected lectures to prepare for the EBIR examination, all in one site! CIRSE Library access is free for CIRSE members year-round. For non-members there are various access purchase options. Find out more at the booth and explore the most extensive online educational resource in interventional radiology at library.cirse.org!

CIRT – FR**14**

Selective Internal Radiation Therapy (SIRT), also known as radioembolisation, is a minimal invasive, endovascular treatment for primary and secondary liver tumours. In France, SIR-Spheres are listed as reimbursable by the national health authorities (Haute Autorité de Santé [HAS]). In order to evaluate the reimbursement after five years, all patients treated with SIR-Spheres will be entered into a registry that collects data on the real-life clinical application of SIRT and reports to the national authorities.

Cook Medical

O'Halloran Road
National Technology Park
Limerick
IRELAND
www.cookmedical.eu

**6**

Since 1963, Cook Medical has worked closely with physicians to develop technologies that eliminate the need for open surgery. Today we are combining medical devices, biologic materials, and cellular therapies to help the world's healthcare systems deliver better outcomes more efficiently. We have always remained family owned so that we have the freedom to focus on what we care about: patients, our employees, and our communities. For more information, visit www.cookmedical.eu, and for the latest news, follow us on Twitter, Facebook, and LinkedIn.

CVIR – CardioVascular and Interventional Radiology**17**

CVIR is the official journal of CIRSE. During the past 40 years, CVIR has established itself as a key source of cutting-edge information, positioning itself as the leading journal in the field of interventional radiology.

CVIR enjoys a vast international readership. In addition to its association with CIRSE, CVIR is also an official organ of various societies representing over 20 countries.

www.cvironline.org

CVIR Endovascular**16**

CVIR Endovascular is CIRSE's online-only, open access journal focusing on endovascular therapies and research relevant to daily IR practice. It features an open peer-review model and is intended for all specialists working in the field of endovascular treatment.

The journal operates on article processing charges. More than 600 institutions worldwide support their affiliated authors in publishing open access by covering part or the entirety of publication costs. Applications for waivers or discounts on article processing charges can be completed during manuscript submission.

www.cvirendovascular.org

**EBIR – The European Board of
Interventional Radiology****11**

This examination is designed to evaluate interventional radiologists on the clinical and technical knowledge necessary to carry out safe and effective treatments for patients. Created by a team of medical experts and a professional educationalist, its content and topic distribution are based on the European Curriculum and Syllabus for Interventional Radiology. Over 600 IRs have already achieved this sought-after qualification, with application numbers steadily on the rise. Applications are submitted online, with two examinations being held in Europe and one examination being held in Australasia each year.

Candidates can draw

on a variety of study tools, such as the CIRSE Library and the CIRSE Academy, to help expand and deepen their knowledge.

Endovascular Today Europe**10a**

1008 Upper Gulph Road, Suite 200

PA 19087 Wayne

UNITED STATES OF AMERICA

www.evtoday.com

Endovascular Today Europe is the premier publication for all specialists engaged in endovascular therapies. Published 7 times a year with a weekly online e-newsletter, each issue of Endovascular Today Europe features timely articles on new techniques, clinical trial results, case studies, and advances in technology for endovascular practitioners. Endovascular Today Europe is distributed to 9,200 endovascular specialists in Europe.

GEM

S.r.l.

Via dei Campi, 2

55049 Viareggio (LU)

ITALY

www.gemitaly.it

**13**

GEM S.r.l., Italian firm since 1994 produces and distributes worldwide synthetic adhesive: Glubran® 2 for Surgical and Endovascular use, Glubran Tiss® 2 for skin treatment and their application devices: Dispensing Tips, Catheters for laparoscopy, Nebulizer Catheters in 5 different models suitable for open

and laparoscopic surgery, Luer lock syringes (1ml) without needle, Vascular Closure Device for femoral access. Glutack® a laparoscopic catheter for atraumatic hernia and laparocele mesh fixation. All CE marked.

Glubran® 2 is an embolizing agent, used in interventional radiology and neuroradiology. The final solution for: AVM, Trauma, Bleedings, Tumors, Varicocele, Portal Vein, Type II endoleaks.

Glubran® 2 is a medical device Class III CE marked for internal and external use. It is a synthetic biodegradable cyanoacrylate based product, modified by the addition of a monomer synthesized by GEM. Glubran® 2, ready for use, is an excellent sealant, a high adhesive, a hemostatic and bacteriostatic product.

GEM evolution comes from continuous commitment to research and effort to improve our products, to demonstrate the efficiency and quality of them, not only with the contribution of internal professional experts, but also with clinical research on the most innovative products. Innovation is part of GEM's DNA as shown by the important results and solutions developed and achieved year after year in response to our clients' needs, working together, testing at site and analyzing results, but progressively, we try to anticipate clients' needs and future technological challenges, working at introducing innovative solutions independently.

GEM development is never complete and we therefore constantly strive towards the improvement of our devices, systems and protocol of uses.

Guerbet

BP 57400

95943 Roissy CDG Cedex

FRANCE

Phone: +33 1 45 91 50 00

Fax: +33 1 45 91 51 99

E-Mail: Direction.Communication@guerbet-group.com

www.guerbet.com



DIAMOND

4

Guerbet | 

Guerbet is a pioneer in the contrast-agent field, with more than 90 years' experience, and is a leader in medical imaging worldwide. It offers a comprehensive range of

pharmaceutical products, medical devices, and services for diagnostic and interventional imaging to improve the diagnosis and treatment of patients. With 8% of revenue dedicated to R&D and more than 200 employees distributed across its four centers in France, Israel, and the United States, Guerbet is a substantial investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €790 million in revenue in 2018. For more information about Guerbet, please visit www.guerbet.com

Interventional News / BIBA

BIBA Medical Ltd
526 Fulham Road
SW6 5NR London
UNITED KINGDOM
E-Mail: shilpa@bibamedical.com
www.interventionalnews.com

**10**

Interventional News is an editorially independent, expertly curated news provider that brings you the news, as it happens. With fortnightly newsletters, a social media presence and a website with worldwide readership, we also have a quarterly print edition for subscribers in Europe and North America. Published by BIBA Medical, Interventional News is steered by renowned editors-in-chief, Professor Andy Adam and Dr. Brian Stainken, and reaches over 12,000 interventionalists. Interventional News contains the latest news, summaries of cutting-edge research and spotlights controversies in interventional radiology. We publish expert analysis, conference coverage and key updates on the latest products and medical device industry. Have you visited us yet? Free subscription at www.interventionalnews.com.

** Corporate sponsors not exhibiting*



EmboCube™

Embolisation Gelatin



Watch the video
to learn more



Merit.com/embocube

SPEED • PRECISION • CONSISTENCY™

Before using refer to Instructions for Use for indications, contraindications, warnings, precautions, and directions for use.

Medtronic International Trading Sàrl.

*

Route du Molliau 31

Case postale

1131 Tolochenaz

SWITZERLAND

Phone: +41 (0)21 802 70 00

Fax: +41 (0)21 802 79 00

www.medtronic.com

As a global leader in medical technology, services and solutions, Medtronic improves the health and lives of millions of people each year. We believe our deep clinical, therapeutic and economic expertise can help address the complex challenges – such as rising costs, aging populations and the burden of chronic disease – faced by families and healthcare systems today. But no one can do it alone. That's why we're committed to partnering in new ways and developing powerful solutions that deliver better patient outcomes.

Founded in 1949 as a medical repair company, we're now among the world's largest medical technology, services and solutions companies, employing more than 85,000 people worldwide, serving physicians, hospitals and patients in more than 155 countries. Join us in our commitment to take healthcare Further, Together. Learn more at Medtronic.com.

Merit Medical

5

Amerikalaan 42


6199AE Maastricht

THE NETHERLANDS

Phone: +31 43 358 82 22

www.merit.com

Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy. We look forward to the ET congress and presenting our high-performance embolotherapy and



Frame & Fill with
Ruby Coil

LANTERN
Microcatheter

Large Volume Detachable Coils



Anchor with
POD

LANTERN
Microcatheter

Pack with

POD Packing Coil

Prior to use, please refer to the Instructions for Use for complete product indications, contraindications, warnings, precautions, potential adverse events, and detailed instructions for use.

Ruby Coil System – Intended Use

The Ruby Coil System is intended for arterial and venous embolizations in the peripheral vasculature.

Potential Adverse Events

Possible complications include, but are not limited to, the following: acute occlusion; air embolism; death; distal embolization; emboli; false aneurysm formation; hematoma or hemorrhage at puncture/access site/site of entry; infection; intracranial hemorrhage; ischemia; neurological deficits including stroke; vessel spasm, thrombosis, dissection, or perforation; thromboembolic episodes; neurological deficits including stroke and possibly death; vascular thrombosis; post-embolization syndrome; revascularization; recanalization; inadequate occlusion; aneurysm rupture; parent artery occlusion; incomplete aneurysm filling.

POD System – Intended Use

The POD System is intended for the endovascular embolization of:

- Intracranial aneurysms
- Other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae
- Arterial and venous embolizations in the peripheral vasculature

Potential Adverse Events

Possible complications include, but are not limited to, the

following: acute occlusion; air embolism; allergic reaction and anaphylaxis from contrast media; aneurysm rupture; arteriovenous fistula; coagulopathy; coil herniation into parent vessel; death; device malfunction; distal embolization; emboli; embolic stroke and other cerebral ischemic events; false aneurysm formation; hematoma or hemorrhage at access site of entry; incomplete aneurysm occlusion; infection; intima dissection; intracranial hemorrhage; ischemia; myocardial infarction; neurological deficits including stroke; parent artery occlusion; peripheral thromboembolic events; post-embolization syndrome; premature device detachment; recanalization; renal failure; respiratory failure; revascularization; thromboembolic episodes; vessel spasm, thrombosis, dissection, or perforation.

Penumbra Delivery Microcatheters – Intended Use

The Penumbra Delivery Microcatheters are intended to assist in the delivery of diagnostic agents, such as contrast media, and therapeutic devices, such as occlusion coils to the peripheral and neuro vasculature.

Potential Adverse Events

Possible complications include, but are not limited to, the following: acute occlusion; hematoma or hemorrhage at access site; death; intracranial hemorrhage; hemorrhage; infection (at access site); distal embolization; ischemia (cardiac and/or cerebral); embolus (air, foreign body, thrombus, plaque); aneurysm perforation; false aneurysm formation; neurological deficits including stroke; vessel spasm, thrombosis, dissection, perforation or rupture; air embolism; emboli.

Penumbra



Product availability varies by country. Renderings for illustrative purposes only. Individual results may vary depending on a variety of patient-specific attributes. Please contact your local Penumbra representative for more information.

Copyright ©2018–2019 Penumbra, Inc. All rights reserved. The Penumbra P logo, Ruby, POD, and LANTERN are registered trademarks or trademarks of Penumbra, Inc. in the USA and other countries. 15072, Rev. B 02/19 OUS

delivery systems portfolios: Embosphere® Microspheres, the most clinically proven round embolic with consistent and predictable results for effective embolization; HepaSphere™ Microspheres, which deliver excellent objective response rates for embolisation of hepatocellular carcinoma and metastases to the liver; SwiftNINJA®, a straight tip catheter that articulates up to 180 degrees in opposing directions to rapidly select the most challenging vascular ostium. True Form™ is a 0.014" reshapable guide wire that can be shaped multiple times and maintain its shape during procedures. Stop-by our booth for a hands-on experience with our newest product: EmboCube™ Embolisation Gelatin – a gelatin foam that is uniformly cut and loaded into a syringe for faster preparation and delivery. EmboCube's calibration helps to facilitate smooth, clog-free delivery of the embolic. We look forward to seeing you.

Penumbra Europe GmbH

Am Borsigturm 44

13507 Berlin

GERMANY

Phone: +49 30 2005 676-0


Fax: +49 30 2005 676-10

E-Mail: info@penumbrainc.de<https://www.penumbrainc.com/de/>**2**


Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets medical devices and has a broad portfolio of products that addresses challenging medical conditions and significant clinical needs.

SIR-Spheres® Y-90 resin microspheres

An alternative treatment option in
neuroendocrine liver metastases^{1,2}



Clinical response in symptomatic patients*



Of malignancy-related
symptomatic patients
experienced clinical
response post-SIRT^{*1}

References:

1. Braat AJAT *et al. Cardiovasc Intervent Radiol* 2019; **42**: 413–425.
2. Frilling A *et al. HPB* 2019; ePub: doi.org/10.1016/j.hpb.2018.12.014

* Clinical response was defined as improvement and complete resolution of pre-treatment complaints

SIRTeX

SIR-Spheres® is a registered trademark
of Sirtex SIR-Spheres Pty Ltd

Sirtex Medical Europe GmbH

Joseph-Schumpeter-Allee 33, 53227 Bonn, Germany
www.sirtex.com

160-E-0319C

Sirtex Medical Europe GmbH

Joseph-Schumpeter-Allee 33

53227 Bonn

GERMANY

Phone: +49 228 1840 730

Fax: +49 228 1840 735

E-Mail: info-emea@sirtex.comwww.sirtex.com**3**

Sirtex Medical is actively engaged in the field of liver-directed therapies for cancer patients.

Our innovative technology, SIR-Spheres® Y-90 resin microspheres (microscopic Yttrium-90 resin beads), is a medical device used in interventional oncology to deliver Selective Internal Radiation Therapy (SIRT) to the liver.

For inoperable primary liver cancer as well as liver metastases, it delivers high doses of radiation directly to the site of tumours whilst preserving normal liver parenchyma. SIR-Spheres Y-90 resin microspheres were approved in 2002 for use in the treatment of unresectable liver tumours within the European Union under a CE Mark.

They are presently used at 300+ institutions in Europe and the Middle East to treat a variety of unresectable liver metastases as well as hepatocellular carcinoma.

SIR-Spheres Y-90 resin microspheres are the most widely studied SIRT technology. Sirtex invested in a robust clinical trial programme of randomised clinical trials involving more than a hundred leading, international medical institutions, a thousand researchers and, more than 2,000 patients.

To date, more than 90,000 treatments have been delivered worldwide.

SIR-Spheres® is a registered trademark of Sirtex
SIR-Spheres Pty Ltd

Terumo Europe NV

Interleuvenlaan 40

3001 Leuven

BELGIUM

Phone: +32 16 38 12 11

www.terumo-europe.com**1**

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with over \$ 5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the health care market and by responding to the needs of health care providers and the people they serve. Terumo develops products for interventional radiologists focused on disease based solutions in liver cancer and non-tumor settings. Rising to the challenge of creating innovative treatments for patients, we bring you a complete range of interventional oncology products that focus on Access, Loco-regional treatments ranging from ablation, TACE and SIRT, Endovascular embolization;


As a pioneer in interventional oncology, Terumo is committed to bringing you cutting-edge technology to support your loco regional patient needs. We are committed to supporting our comprehensive product portfolio by a well-trained field force and solid clinical evidence.



The ET 2019 event in the CIRSE society app

Your toolkit for ET 2019 in Valencia:

- browse the programme
- build your personal schedule
- complete the session evaluation
- participate in e-voting polls
- send questions to the moderators
- find your way around using the interactive floor plan
- browse the list of exhibitors
- watch sessions live and on demand
- and much more...



Available for iOS and Android

Imprint

CIRSE Central Office

Neutorgasse 9
1010 Vienna, Austria

Phone: +43 1 904 2003

Fax: +43 1 904 2003 30

Email: info@cirse.org

www.ETconference.org

The ET 2019 Pocket Guide

In case of any queries or comments,
please contact us at **info@cirse.org**

© Cardiovascular and Interventional Radiological Society
of Europe / 2019


GraphX by L O O P . E N T E R P R I S E S media
www.loop-enterprises.com



MIX
Paper from
responsible sources
FSC® C001924

ET2019

Valencia Conference Centre




Exhibitors (Alphabetical List)

Company	Booth #				
Balt International	7	Cook Medical	6	Guerbet	4
BTG	12	CVIR	17	Interventional News / BIBA	10
CIREL	15	CVIR Endovascular	16	Merit Medical	5
CIRSE Academy	8	EBIR	11	Penumbra Europe	2
CIRSE Library	9	Endovascular Today	10a	Sirtex Medical Europe	3
CIRT-FR	14	GEM	13	Terumo Europe	1


LIPIODOL® ULTRA FLUID

Ethyl ester of iodized fatty acids of poppy seed oil

Mastering polymerization time^{1,2,3,4} for a better management of Vascular Anomalies Embolization^{5,6}



POLYMERIZATION TIME ADJUSTMENT | VISIBILITY^{1,4} | CONTROL^{1,4}

Guerbet | 

LIPIODOL® ULTRA-FLUID. Composition: Ethyl esters of iodized fatty acids of poppy seed oil 10 mL, corresponding to an iodine content of 480 mg/mL. **Indications (**):** In diagnostic radiology - Hysterosalpingography - Ascending urethrography - Lymphography - Sialography - Fistulography and exploration of abscesses - Exploration of frontal sinuses - Pre and post-operative cholangiography. In interventional radiology - Visualisation and localization (by selective intra-arterial use during CT) of liver lesions in adults with known or suspected hepatocellular carcinoma - Visualisation, localisation and vectorisation during Trans-Arterial Chemo-Embolisation (TACE) of hepatocellular carcinoma at intermediate stage, in adults - Selective embolization in combination with Histoacryl glue (particularly for arteriovenous malformation or aneurysms) - Selective injections of LIPIODOL ULTRA-FLUID into the hepatic artery for diagnostic purposes where a spiral CT scan is not practical. In endocrinology - Prevention of severe cases of iodine deficiency. **Poology and method of administration (**):** have to be adapted according to the type of examination, the territories explored, the age and weight of the patient. The volume to be administered depends on the particular requirements of the technique and the size of the patient. **Contraindications:** Hypersensitivity to LIPIODOL ULTRA-FLUID - Confirmed hyperthyroidism - Patients with traumatic injuries, recent haemorrhage or bleeding - Hysterosalpingography during pregnancy or acute pelvic inflammation - Bronchography. In interventional radiology (Trans-Arterial Chemo-Embolisation). Administration in liver areas with dilated bile ducts unless drainage has been performed. **Special warnings and special precautions for use (**):** There is a risk of hypersensitivity regardless of the dose administered. Lymphography: Pulmonary embolism may occur immediately or after few hours to days from inadvertent systemic vascular injection or intravasation of LIPIODOL ULTRA-FLUID: Perform radiological monitoring during LIPIODOL ULTRA-FLUID injection and avoid use in patients with severely impaired lung function, cardiorespiratory failure or right-sided cardiac overload. Hypersensitivity: all iodinated contrast agents can lead to minor or major hypersensitivity reactions, which can be life-threatening. These hypersensitivity reactions are of an allergic nature (known as anaphylactic reactions if they are serious) or a non-allergic nature. They can be immediate (occurring within 60 min) or delayed (not occurring until up to 7 days later). Anaphylactic reactions are immediate and can be fatal. They are dose-independent, can occur right from the first administration of the product, and are often unpredictable: avoid use in patients with a history of sensitivity to other iodinated contrast agents, bronchial asthma or allergic disorders because of an increased risk of a hypersensitivity reaction to LIPIODOL ULTRA-FLUID. Thyroid: can cause hyperthyroidism in predisposed patients. Lymphography saturates the thyroid with iodine for several months and thyroid exploration should be performed before radiological examination. Chemo-Embolization: Trans-Arterial Chemo-Embolization is not recommended in patients with decompensated liver cirrhosis (Child-Pugh >8), advanced liver dysfunction, macroscopic invasion and/or extra-hepatic spread of the tumour. Renal insufficiency must be prevented by correct rehydration before and after the procedure. Oesophageal varices must be carefully monitored. Hepatic intra-arterial treatment can progressively cause an irreversible liver insufficiency in patients with serious liver malfunction and/or undergoing close multiple sessions. The risk of superinfection in the treated area is normally prevented by administration of antibiotics. Embolization with glue: An early polymerisation reaction may exceptionally occur between LIPIODOL ULTRA-FLUID and certain surgical glues, or even certain batches of glue. Before using new batches of LIPIODOL ULTRA-FLUID or surgical glue, the compatibility of LIPIODOL ULTRA-FLUID and the glue must be tested in vitro. **Interaction with other medicinal products and other forms of interaction (**):** Metformin, Beta blockers, vasoactive substances, angiotensin-converting enzyme inhibitors, angiotensin-receptor antagonists, Diuretics, Interleukin II. **Fertility, pregnancy and lactation (**):** LIPIODOL ULTRA-FLUID must only be used in pregnant women if absolutely necessary and under strict medical supervision. Breastfeeding should be discontinued if LIPIODOL ULTRA-FLUID must be used. **Effects on ability to drive and use machines:** The effects on ability to drive and to use machines have not been investigated. **Undesirable effects (**):** Most adverse effects are dose-related and dosage should therefore be kept as low as possible: hypersensitivity, anaphylactic reaction, anaphylactoid reaction, vomiting, diarrhea, nausea, fever, pain, dyspnea, cough, hypothyroidism, hyperthyroidism, thyroiditis, pulmonary embolism, cerebral embolism, retinal vein thrombosis, lymphoedema aggravation, hepatic vein thrombosis, granuloma. **Overdose (**):** The total dose of LIPIODOL ULTRA-FLUID administered must not exceed 20 mL. **Pharmacodynamic properties (**):** Pharmacotherapeutic group: X-ray contrast media, iodinated, ATC code: V08A D01. Water-insoluble iodinated contrast medium. **Presentation (**):** 10 mL glass ampoule. **Marketing authorization holder (**):** Guerbet - BP 57400 - F-95943 Roissy Cedex - FRANCE. Information: tel: 33 (0) 1 45 91 50 00. **Revision:** April 24th, 2018.

(*) For complete information please refer to the local Summary of Product Characteristics (SPC).

(**) Indications, volumes and presentations may differ from country to country.

Reporting of suspected adverse reactions is important as it helps to continuously assess the benefit-risk balance. Therefore, Guerbet encourages you to report any adverse reactions to your health authorities or to our local Guerbet representative.

1. Takeuchi Y, et al., Guidelines for the use of NBCA in vascular embolization devised by the Committee of Practice Guidelines of the Japanese Society of Interventional Radiology (JGIR), 2012 edition, Jpn J Radiol, 2014; 32:500-517. 2. IEE BB, et al., Consensus Document of the International Union of Angiology (IUA) 2013 Current concepts on the management of arterio-venous malformations, International Angiology, 2013;32(1):11-36. 3. Seewald S et al., A standardized injection technique and regimen ensures success and safety of N-butyl-2-cyanoacrylate injection for the treatment of gastric fundal varices, Gastrointestinal endoscopy, 2008;68(3): 447-454. 4. American Society for Gastrointestinal Endoscopy. Tissue adhesives: cyanoacrylate glue and fibrin sealant, Gastrointestinal Endoscopy, 2013;78: 2, 209-215. 5. Madhusudan KS, et al., Endovascular Embolization of Visceral Artery Pseudoaneurysms Using Modified Injection Technique with N-Butyl Cyanoacrylate Glue, J Vasc Interv Radiol, 2013;26:1718-1725. 6. Lo GH, et al., A Prospective, Randomized Trial of Butyl Cyanoacrylate Injection Versus Band Ligation in the Management of Bleeding Gastric Varices, Hepatology, 2001; 33(5), 1060-1064.